Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical TechnologyTelomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower doseNext: Symeres and Ambagon collaborate for colorectal cancer molecules Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
